|
gptkbp:instanceOf
|
gptkb:COVID-19
antiviral drug
|
|
gptkbp:activeIngredient
|
gptkb:nirmatrelvir
gptkb:ritonavir
|
|
gptkbp:age
|
adults
children 12 years and older weighing at least 40 kg
|
|
gptkbp:approvalYear
|
December 2021
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:U.S._Food_and_Drug_Administration
December 2021
treatment of COVID-19
|
|
gptkbp:ATCCode
|
gptkb:J05AE
|
|
gptkbp:brand
|
gptkb:Paxlovid
|
|
gptkbp:contraindication
|
severe renal impairment
severe hepatic impairment
|
|
gptkbp:cost
|
varies by country and insurance
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugInteraction
|
CYP3A substrates
|
|
gptkbp:effect
|
reduces risk of hospitalization and death in high-risk COVID-19 patients
|
|
gptkbp:emergencyServices
|
granted by FDA
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:nirmatrelvir/ritonavir
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Paxlovid
|
|
gptkbp:indication
|
patients at high risk for progression to severe COVID-19
mild to moderate COVID-19
|
|
gptkbp:lactation
|
caution advised
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
protease inhibitor
inhibits SARS-CoV-2 main protease (Mpro)
|
|
gptkbp:notRecommendedFor
|
patients with severe kidney or liver disease
|
|
gptkbp:patent
|
gptkb:Pfizer
|
|
gptkbp:pregnancyCategory
|
not recommended unless clearly needed
|
|
gptkbp:prescriptionRequired
|
available from Pfizer
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:reboundEffect
|
possible COVID-19 symptom recurrence after treatment
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
muscle aches
high blood pressure
altered sense of taste
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
5 days
|
|
gptkbp:WHOEssentialMedicinesList
|
included
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
|
|
gptkbp:bfsLayer
|
4
|